Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.09B

Market cap19.09B

Price-Earnings ratio

14.71

Price-Earnings ratio14.71

Dividend yield

—

Dividend yield—

Average volume

1.72M

Average volume1.72M

High today

$96.05

High today$96.05

Low today

$92.55

Low today$92.55

Open price

$93.02

Open price$93.02

Volume

1.16M

Volume1.16M

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

With a market cap of 19.09B, Incyte(INCY) trades at $95.04. The stock has a price-to-earnings ratio of 14.71.

On 2026-04-03, Incyte(INCY) stock moved within a range of $92.55 to $96.05. With shares now at $95.04, the stock is trading +2.7% above its intraday low and -1.1% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.16M, versus its average volume of 1.72M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

TipRanks 21h

Adagene enters pact with Incyte for combination of muzastotug, INCA33890

Adagene (ADAG) announced a clinical collaboration with Incyte (INCY) to evaluate the combination of muzastotug and INCA33890, a TGFbetaR2 PD-1 bispecific antibo...

Simply Wall St 1d

Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The...

Simply Wall St 3d

Assessing Incyte Valuation After Recent Share Price Weakness And Mixed Fair Value Signals

Without a specific news catalyst, Incyte (INCY) has attracted attention after a period where the share price shows a one-month return of about negative 11% and...

Analyst ratings

50%

of 28 ratings

Buy

39.3%

Hold

50%

Sell

10.7%

More INCY News

TipRanks 3d

Incyte Announces Upcoming Resignation of Board Member Schaffert

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 5d

Incyte announces new 54-week data on safety, efficacy of povorcitinib

Incyte (INCY) announced 54-week data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 inhibitor, from the pivota...

Simply Wall St 6d

The Bull Case For Incyte Could Change Following Its U.S. Commercial Leadership Shake-Up – Learn Why

Earlier this week, Incyte reshaped its leadership team, elevating Pablo J. Cagnoni, M.D., to President and Global Head of R&D, expanding Steven Stein, M.D.’s re...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

AMD

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.